Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,961 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06346912 | CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL | recruiting | Early Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06329908 | DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs | recruiting | Early Phase 1 | 20 | Zhen-Yu DingOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06327997 |
| An Exploratory Study by Fast CAR T Cells |
| recruiting |
| Early Phase 1 |
| 20 |
| Shanghai Cell Therapy Group Co.,LtdINDUSTRY |
| 1 |
| Mar 25, 2024 |
| clinicaltrials |
| NCT06326736 | Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer | recruiting | Early Phase 1 | 12 | Jinling Hospital, ChinaOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT05069220 | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor | recruiting | Early Phase 1 | 150 | Peking Union Medical College HospitalOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT06248697 | Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors | recruiting | Early Phase 1 | 16 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06249256 | An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells | recruiting | Early Phase 1 | 12 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06152757 | BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors | recruiting | Early Phase 1 | 14 | BioSyngen Pte LtdINDUSTRY | 1 | Dec 1, 2023 | clinicaltrials |
| NCT06104241 | BGT007 Cells for the Treatment of Refractory Digestive System Tumors | recruiting | Early Phase 1 | 14 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT05916261 | Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer | recruiting | Early Phase 1 | 54 | Ruijin HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06045091 | To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL | recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05811975 | KSX01-TCRT Injection Project in Solid Tumors | recruiting | Early Phase 1 | 50 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05539833 | KSH01-TCRT Solid Tumors(KSH01-TCRT) | recruiting | Early Phase 1 | 50 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05580796 | KSH01-R02-101 Solid Tumors | recruiting | Early Phase 1 | 50 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05753657 | A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer. | recruiting | Early Phase 1 | 30 | Rambam Health Care CampusOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT04657861 | APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05141253 | Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors | recruiting | Early Phase 1 | 24 | Tongji HospitalOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05166070 | An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors | recruiting | Early Phase 1 | 24 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT04662294 | CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases | recruiting | Early Phase 1 | 108 | Zhejiang UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04227015 | A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy | recruiting | Early Phase 1 | 72 | He HuangOTHER | 1 | Dec 28, 2020 | clinicaltrials |
| NCT04603872 | CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies | recruiting | Early Phase 1 | 120 | Zhejiang UniversityOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT04532203 | A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies | recruiting | Early Phase 1 | 72 | Zhejiang UniversityOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT04532281 | A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies | recruiting | Early Phase 1 | 120 | Zhejiang UniversityOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT02446431 | Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence(Metronomic) | recruiting | Early Phase 1 | 20 | Miller Children's & Women's Hospital Long BeachOTHER | 1 | May 18, 2015 | clinicaltrials |
Data updated 22 days agoSource updated May 14, 2024source: clinicaltrials